Trial Profile
An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With RCHOP Chemotherapy and Rituximab (MabThera) Maintenance in Patients With First-line Advanced Follicular Non Hodgkin's Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- 24 Mar 2012 Actual initiation date (19 Sep 2008) added as reported by European Clinical Trials Database.
- 24 Mar 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
- 13 May 2009 New trial record